Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2024-10-21 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
第六届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the sixth board of directors' third meeting of Xintiandi Pharmaceutical Co., Ltd. It includes approval of the 2024 third quarter report, adjustments to fundraising projects, amendments to the company's articles of association, governance system revisions, and the proposal to convene an extraordinary shareholders meeting. The document references that the full 2024 third quarter report and other detailed announcements are disclosed separately on the official information website (cninfo.com.cn). The document itself does not contain the full financial statements or substantive financial data but rather the board's resolutions and approvals. It is a formal announcement of board meeting decisions, including governance and procedural matters, not the actual reports or financial statements. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2024-10-21 Chinese
日常生产经营决策制度
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '日常生产经营决策制度' (Daily Production and Operation Decision System) for a company, outlining procedures and rules for daily business operations and contract management. It does not contain financial statements, audit results, earnings data, or any form of report publication or announcement. It is a governance-related document describing internal rules and decision-making processes approved by the board. Therefore, it fits best under Governance Information (CGR). The document length is 2755 characters, which is relatively short but contains substantive governance content rather than an announcement or summary.
2024-10-21 Chinese
关于部分募投项目调整产品品种、部分募投项目内部投资结构调整及延期的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company about adjustments to certain fundraising investment projects, including changes in product varieties, internal investment structure adjustments, and project delays. It includes specifics about the use of funds raised from a public stock issuance, approvals from various company boards and committees, and regulatory compliance statements. The document is not a full financial report, earnings release, or audit report, but rather an official announcement regarding capital use and project adjustments related to fundraising activities. It is not a simple notice or a brief summary but a comprehensive disclosure about capital project changes and fundraising usage. Therefore, the document fits best into the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2024-10-21 Chinese
关于修订《公司章程》及修订和新增相关治理制度的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding the revision of the company's Articles of Association (公司章程) and related governance systems. It includes extensive text about changes in company governance, shareholder rights, board responsibilities, capital structure, and other corporate governance matters. The document is not a financial report, earnings release, or audit report. It is not a brief announcement but a substantive governance-related document. The content aligns with a Governance Information report, which details the company's internal rules, board structure, and governance practices. Therefore, the appropriate classification is Governance Information (CGR).
2024-10-21 Chinese
舆情管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '舆情管理制度' (Public Opinion Management System) of 新天地药业股份有限公司. It outlines the company's procedures and responsibilities for managing public opinion and media reports that could affect the company's stock price and reputation. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no management changes, no capital updates, no earnings information, or any other typical financial or regulatory report content. It is a governance-related internal policy document focused on crisis and media management. Therefore, it best fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-10-21 Chinese
董事会议事规则
Governance Information Classification · 100% confidence The document is titled '董事会议事规则' which translates to 'Board Meeting Rules' or 'Rules of Procedure for the Board of Directors'. It details the structure, powers, meeting procedures, voting rules, and responsibilities of the board of directors of the company. It references company law, governance codes, and internal company bylaws. There is no financial data, no report on financial performance, no announcement of voting results, no management changes, no earnings or capital updates, and no legal proceedings. The content is focused on governance practices and internal rules of the board. Therefore, this document fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance rules, confirming it is not a mere announcement or a short notice.
2024-10-21 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.